Evidence map›Paper›PMID 41991710›Full record

ArticleApplied microbiology and biotechnology2026

The combination of mupirocin and Kayvirus broadens the decolonization effect against Staphylococcus aureus.

Alena Siváková, Eliška Figallová, Tibor Botka, Lukáš Vacek, Jan Tkadlec, Jan Vrbský, Martin Osowski, Petr Petráš, Dominika Polaštík Kleknerová, Milada Dvořáčková and 3 more

Erratum issuedAbstract read
In one paragraph

Article in Applied microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Alena Siváková *Department of Microbiology, Faculty of Medicine, Masaryk University and St. Anne's University Hospital, Brno, Czech Republic.ORCID http://orcid.org/0000-0002-9224-4613
Eliška Figallová *Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.ORCID http://orcid.org/0000-0002-4115-0385
Tibor BotkaDepartment of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic. tibor.botka@mail.muni.cz.ORCID http://orcid.org/0000-0003-2708-3718
Lukáš VacekDepartment of Microbiology, Faculty of Medicine, Masaryk University and St. Anne's University Hospital, Brno, Czech Republic.ORCID http://orcid.org/0000-0002-2045-2456
Jan TkadlecDepartment of Medical Microbiology, Second Faculty of Medicine, Charles University and University Hospital Motol and Homolka, Prague, Czech Republic.ORCID http://orcid.org/0000-0002-0892-924X
Jan VrbskýDepartment of Microbiology, Faculty of Medicine, Masaryk University and St. Anne's University Hospital, Brno, Czech Republic.ORCID http://orcid.org/0000-0002-1406-2929
Martin OsowskiDepartment of Microbiology, Faculty of Medicine, Masaryk University and St. Anne's University Hospital, Brno, Czech Republic.ORCID http://orcid.org/0009-0008-8510-471X
Petr PetrášNational Reference Laboratory for Staphylococci, National Institute of Public Health, Prague, Czech Republic.ORCID http://orcid.org/0000-0002-1178-8476
Dominika Polaštík KleknerováDepartment of Microbiology, Faculty of Medicine, Masaryk University and St. Anne's University Hospital, Brno, Czech Republic.ORCID http://orcid.org/0000-0001-6007-2215
Milada DvořáčkováDepartment of Microbiology, Faculty of Medicine, Masaryk University and St. Anne's University Hospital, Brno, Czech Republic.ORCID http://orcid.org/0000-0002-7752-3825
Pavlína UrbanováDepartment of Microbiology, Faculty of Medicine, Masaryk University and St. Anne's University Hospital, Brno, Czech Republic.ORCID http://orcid.org/0009-0000-3708-252X
Roman PantůčekDepartment of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.ORCID http://orcid.org/0000-0002-3950-675X
Filip RůžičkaDepartment of Microbiology, Faculty of Medicine, Masaryk University and St. Anne's University Hospital, Brno, Czech Republic.ORCID http://orcid.org/0000-0001-5679-0513

Funding

Masarykova Univerzita MUNI/A/1759/2025Ministerstvo Zdravotnictví Ceské Republiky NU21J-05-00035
6 · The paper itself

Abstract

Staphylococcus aureus strains cause a wide range of infections in humans, often with the potential for complications such as surgical site infections. The production of Panton-Valentin leukocidin (PVL) by certain strains of S. aureus is clinically associated with chronic or recurrent infections, which typically require decolonization, most often with mupirocin. As increased mupirocin use promotes the emergence of resistance, this study investigated the coadministration of mupirocin and therapeutic Kayvirus bacteriophage as a potential strategy to enhance treatment efficacy and prevent the development of new resistance. We collected and evaluated 37 PVL-encoding S. aureus strains from wound samples. Among these, 22% were methicillin-resistant, and 11% were resistant to the tested phage, but all were susceptible to mupirocin. To assess interactions between mupirocin and the phage in PVL-positive strains with varying levels of mupirocin resistance, we used lysogenization by PVL-encoding phage and adaptive laboratory evolution of clinical strains. In mupirocin-susceptible strains, lytic phage efficacy decreased due to altered protein synthesis caused by the interaction of mupirocin with isoleucyl-tRNA synthetase, whereas mupirocin efficacy was unaffected. In contrast, the advantage of combined administration was observed in mupirocin-resistant strains susceptible to phages, as their altered or alternative synthetase allowed protein synthesis to continue, enabling phage proliferation and bacterial lysis, even in the presence of mupirocin. This in vitro study demonstrates that mupirocin in combination with Kayvirus broadens the spectrum of strains susceptible to treatment and that the phage used prevents the development of mupirocin resistance. KEY POINTS: • Mupirocin-phage combination broadens the anti-staphylococcal effect in vitro. • Combination treatment reduces the emergence of mupirocin resistance. • Mupirocin action is not inhibited by phage therapy.

Indexed as

Anti-Bacterial AgentsMupirocinStaphylococcal InfectionsStaphylococcus aureusStaphylococcus PhagesBacterial ToxinsDrug Resistance, BacterialExotoxinsHumansIsoleucine-tRNA LigaseLeukocidinsLysogenyAnti-Bacterial AgentsBacterial ToxinsExotoxinsIsoleucine-tRNA LigaseLeukocidinsMupirocinPanton-Valentine leukocidinDecolonizationKayvirusMupirocinPanton-Valentine leukocidinPhage therapyStaphylococcus aureus

Identifiers

PMID41991710
PMCPMC13201327

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.